Although clinical studies of vaccine efficacy will ultimately be needed

we must also begin now to investigate correlates of human immunity after both natural SARS-CoV-2 infection and vaccination, including by evaluating the durability of responses and their localization (mucosal and systemic).

Human challenge [!] studies with the human "cold virus" coronaviruses (e.g., OC43) will probably be important.